Kotaro Hattori

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4507610/publications.pdf

Version: 2024-02-01

75 papers

2,348 citations

236925
25
h-index

243625 44 g-index

78 all docs 78 docs citations

times ranked

78

4449 citing authors

#	Article	IF	CITATIONS
1	Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. Journal of Affective Disorders, 2016, 202, 254-257.	4.1	419
2	Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. Journal of Psychiatric Research, 2013, 47, 401-406.	3.1	166
3	Genome-Wide Association Study Detected Novel Susceptibility Genes for Schizophrenia and Shared Trans-Populations/Diseases Genetic Effect. Schizophrenia Bulletin, 2019, 45, 824-834.	4.3	109
4	Plasma Metabolites Predict Severity of Depression and Suicidal Ideation in Psychiatric Patients-A Multicenter Pilot Analysis. PLoS ONE, 2016, 11, e0165267.	2.5	103
5	Bifidobacterium and Lactobacillus Counts in the Gut Microbiota of Patients With Bipolar Disorder and Healthy Controls. Frontiers in Psychiatry, 2018, 9, 730.	2.6	73
6	Effect of electroconvulsive therapy on gray matter volume in major depressive disorder. Journal of Affective Disorders, 2015, 186, 186-191.	4.1	72
7	Effect of a ketogenic meal on cognitive function in elderly adults: potential for cognitive enhancement. Psychopharmacology, 2016, 233, 3797-3802.	3.1	62
8	Plasma amino acid profile in major depressive disorder: Analyses in two independent case-control sample sets. Journal of Psychiatric Research, 2018, 96, 23-32.	3.1	54
9	White matter abnormalities in major depressive disorder with melancholic and atypical features: A diffusion tensor imaging study. Psychiatry and Clinical Neurosciences, 2015, 69, 360-368.	1.8	51
10	Structural differences in hippocampal subfields among schizophrenia patients, major depressive disorder patients, and healthy subjects. Psychiatry Research - Neuroimaging, 2017, 259, 54-59.	1.8	50
11	Fyn Is Required for Haloperidol-induced Catalepsy in Mice. Journal of Biological Chemistry, 2006, 281, 7129-7135.	3.4	45
12	Pseudo-continuous arterial spin labeling MRI study of schizophrenic patients. Schizophrenia Research, 2014, 154, 113-118.	2.0	43
13	Association of obesity with cognitive function and brain structure in patients with major depressive disorder. Journal of Affective Disorders, 2018, 225, 188-194.	4.1	43
14	Increased cerebrospinal fluid fibrinogen in major depressive disorder. Scientific Reports, 2015, 5, 11412.	3.3	42
15	Reduced cerebrospinal fluid ethanolamine concentration in major depressive disorder. Scientific Reports, 2015, 5, 7796.	3.3	41
16	Effect of <scp>l</scp> -theanine on glutamatergic function in patients with schizophrenia. Acta Neuropsychiatrica, 2015, 27, 291-296.	2.1	37
17	The common functional FKBP5 variant rs1360780 is associated with altered cognitive function in aged individuals. Scientific Reports, 2014, 4, 6696.	3.3	36
18	Genome-wide quantitative trait loci mapping of the human cerebrospinal fluid proteome. Human Molecular Genetics, 2017, 26, ddw366.	2.9	35

#	Article	IF	Citations
19	Association between vascular endothelial growth factor-mediated blood–brain barrier dysfunction and stress-induced depression. Molecular Psychiatry, 2022, 27, 3822-3832.	7.9	35
20	Effect of the common functional FKBP5 variant (rs1360780) on the hypothalamic-pituitary-adrenal axis and peripheral blood gene expression. Psychoneuroendocrinology, 2014, 42, 89-97.	2.7	34
21	Characteristic distributions of regional cerebral blood flow changes in major depressive disorder patients: A pseudo-continuous arterial spin labeling (pCASL) study. Journal of Affective Disorders, 2014, 165, 59-63.	4.1	34
22	Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. Biochemical and Biophysical Research Communications, 2018, 497, 683-688.	2.1	34
23	Effects of ankyrin 3 gene risk variants on brain structures in patients with bipolar disorder and healthy subjects. Psychiatry and Clinical Neurosciences, 2016, 70, 498-506.	1.8	33
24	Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia. Journal of Psychiatric Research, 2019, 113, 190-198.	3.1	32
25	Association between the common functional FKBP5 variant (rs1360780) and brain structure in a non-clinical population. Journal of Psychiatric Research, 2014, 58, 96-101.	3.1	27
26	Blood-based gene expression signatures of medication-free outpatients with major depressive disorder: integrative genome-wide and candidate gene analyses. Scientific Reports, 2016, 6, 18776.	3. 3	25
27	Altered polyunsaturated fatty acid levels in relation to proinflammatory cytokines, fatty acid desaturase genotype, and diet in bipolar disorder. Translational Psychiatry, 2019, 9, 208.	4.8	25
28	Cerebrospinal fluid neuroplasticity-associated protein levels in patients with psychiatric disorders: a multiplex immunoassay study. Translational Psychiatry, 2020, 10, 161.	4.8	25
29	Altered Coupling of Regional Cerebral Blood flow and Brain Temperature in Schizophrenia Compared with Bipolar Disorder and Healthy Subjects. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 1868-1872.	4.3	24
30	ITIH3 polymorphism may confer susceptibility to psychiatric disorders by altering the expression levels of GLT8D1. Journal of Psychiatric Research, 2014, 50, 79-83.	3.1	24
31	13C-tryptophan breath test detects increased catabolic turnover of tryptophan along the kynurenine pathway in patients with major depressive disorder. Scientific Reports, 2015, 5, 15994.	3.3	24
32	Relationships of Cerebrospinal Fluid Monoamine Metabolite Levels With Clinical Variables in Major Depressive Disorder. Journal of Clinical Psychiatry, 2017, 78, e947-e956.	2.2	24
33	Relationship between Lifetime Suicide Attempts and Schizotypal Traits in Patients with Schizophrenia. PLoS ONE, 2014, 9, e107739.	2.5	23
34	<p>Reduced plasma orexin-A levels in patients with bipolar disorder</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 2221-2230.	2.2	23
35	More severe impairment of manual dexterity in bipolar disorder compared to unipolar major depression. Journal of Affective Disorders, 2012, 136, 1047-1052.	4.1	22
36	Metabolic profile alterations in the postmortem brains of patients with schizophrenia using capillary electrophoresis-mass spectrometry. Schizophrenia Research, 2017, 183, 70-74.	2.0	22

3

#	Article	IF	Citations
37	Relationship of Handgrip Strength and Body Mass Index With Cognitive Function in Patients With Schizophrenia. Frontiers in Psychiatry, 2018, 9, 156.	2.6	21
38	Association between the scores of the Japanese version of the Brief Assessment of Cognition in Schizophrenia and wholeâ€brain structure in patients with chronic schizophrenia: A voxelâ€based morphometry and diffusion tensor imaging study. Psychiatry and Clinical Neurosciences, 2017, 71, 826-835.	1.8	20
39	Integrated profiling of phenotype and blood transcriptome for stress vulnerability and depression. Journal of Psychiatric Research, 2018, 104, 202-210.	3.1	20
40	Cerebrospinal fluid neural cell adhesion molecule levels and their correlation with clinical variables in patients with schizophrenia, bipolar disorder, and major depressive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 12-18.	4.8	19
41	Increased Matrix Metalloproteinases in Cerebrospinal Fluids of Patients With Major Depressive Disorder and Schizophrenia. International Journal of Neuropsychopharmacology, 2020, 23, 713-720.	2.1	18
42	Cerebrospinal Fluid Inflammatory Cytokine Levels in Patients With Major Psychiatric Disorders: A Multiplex Immunoassay Study. Frontiers in Pharmacology, 2020, 11, 594394.	3.5	18
43	Possible role of the dopamine D1 receptor in the sensorimotor gating deficits induced by high-fat diet. Psychopharmacology, 2015, 232, 4393-4400.	3.1	17
44	Cognitive effects of the ANK3 risk variants in patients with bipolar disorder and healthy individuals. Journal of Affective Disorders, 2014, 158, 90-96.	4.1	15
45	Expression of Ca2+-dependent activator protein for secretion 2 is increased in the brains of schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1738-1743.	4.8	14
46	Cerebrospinal fluid D-serine concentrations in major depressive disorder negatively correlate with depression severity. Journal of Affective Disorders, 2018, 226, 155-162.	4.1	14
47	Manual dexterity and brain structure in patients with schizophrenia: A whole-brain magnetic resonance imaging study. Psychiatry Research - Neuroimaging, 2018, 276, 9-14.	1.8	14
48	Characterization of Postprandial Effects on CSF Metabolomics: A Pilot Study with Parallel Comparison to Plasma. Metabolites, 2020, 10, 185.	2.9	14
49	13C-phenylalanine breath test and serum biopterin in schizophrenia, bipolar disorder and major depressive disorder. Journal of Psychiatric Research, 2018, 99, 142-150.	3.1	13
50	Profiling of Cerebrospinal Fluid Lipids and Their Relationship with Plasma Lipids in Healthy Humans. Metabolites, 2021, 11, 268.	2.9	13
51	Reduced Serum and Cerebrospinal Fluid Levels of Autotaxin in Major Depressive Disorder. International Journal of Neuropsychopharmacology, 2019, 22, 261-269.	2.1	11
52	Correlation Between the Wechsler Adult Intelligence Scale- 3rd Edition Metrics and Brain Structure in Healthy Individuals: A Whole-Brain Magnetic Resonance Imaging Study. Frontiers in Human Neuroscience, 2020, 14, 211.	2.0	11
53	Altered ethanolamine plasmalogen and phosphatidylethanolamine levels in blood plasma of patients with bipolar disorder. Psychiatry and Clinical Neurosciences, 2020, 74, 204-210.	1.8	10
54	Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder. Psychiatry Research, 2017, 254, 244-250.	3.3	10

#	Article	IF	Citations
55	Lysophosphatidic acid levels in cerebrospinal fluid and plasma samples in patients with major depressive disorder. Heliyon, 2019, 5, e01699.	3.2	9
56	Association between lower estimated premorbid intelligence quotient and smoking behavior in patients with schizophrenia. Schizophrenia Research: Cognition, 2019, 15, 7-13.	1.3	9
57	Benzodiazepines, benzodiazepine-like drugs, and typical antipsychotics impair manual dexterity in patients with schizophrenia. Journal of Psychiatric Research, 2014, 49, 37-42.	3.1	8
58	The relationship between the Wechsler Memory Scale-Revised scores and whole-brain structure in patients with schizophrenia and healthy individuals. Cognitive Neuropsychiatry, 2019, 24, 80-91.	1.3	7
59	Levels of lysophosphatidic acid in cerebrospinal fluid and plasma of patients with schizophrenia. Psychiatry Research, 2019, 273, 331-335.	3.3	7
60	Reduced Cerebrospinal Fluid Levels of Lysophosphatidic Acid Docosahexaenoic Acid in Patients With Major Depressive Disorder and Schizophrenia. International Journal of Neuropsychopharmacology, 2021, 24, 948-955.	2.1	7
61	Temperament and character in remitted and symptomatic patients with schizophrenia: Modulation by the COMT Val158Met genotype. Journal of Psychiatric Research, 2014, 56, 82-89.	3.1	6
62	A personality-based latent class typology of outpatients with major depressive disorder: association with symptomatology, prescription pattern and social function. Journal of Affective Disorders, 2017, 217, 8-15.	4.1	6
63	Association of body mass index-related single nucleotide polymorphisms with psychiatric disease and memory performance in a Japanese population. Acta Neuropsychiatrica, 2017, 29, 299-308.	2.1	6
64	Correlation of reduced social communicational and interactional skills with regional grey matter volumes in schizophrenia patients. Acta Neuropsychiatrica, 2017, 29, 374-381.	2.1	5
65	Low cocaine- and amphetamine-regulated transcript (CART) peptide levels in human cerebrospinal fluid of major depressive disorder (MDD) patients. Journal of Affective Disorders, 2018, 232, 134-138.	4.1	5
66	Increased apolipoprotein E and decreased TNFâ€Î± in the cerebrospinal fluid of nondemented APOEâ€Îµ4 carriers. Neuropsychopharmacology Reports, 2020, 40, 201-205.	2.3	5
67	Possible associations between plasma fibroblast growth factor 21 levels and cognition in bipolar disorder. Neuropsychopharmacology Reports, 2020, 40, 175-181.	2.3	5
68	Association between obesity and white matter microstructure impairments in patients with schizophrenia: A whole-brain magnetic resonance imaging study. Schizophrenia Research, 2021, 230, 108-110.	2.0	4
69	Lower cerebrospinal fluid CRH concentration in chronic schizophrenia with negative symptoms. Journal of Psychiatric Research, 2020, 127, 13-19.	3.1	4
70	Blood CADPS2ΔExon3 expression is associated with intelligence and memory in healthy adults. Biological Psychology, 2012, 89, 117-122.	2.2	3
71	Relationship between Autistic Spectrum Trait and Regional Cerebral Blood Flow in Healthy Male Subjects. Psychiatry Investigation, 2018, 15, 956-961.	1.6	2
72	Haplotype phasing of a bipolar disorder pedigree revealed rare multiple mutations of SPOCD1 gene in the 1p36–35 susceptibility locus. Journal of Affective Disorders, 2022, 310, 96-105.	4.1	2

#	Article	IF	CITATIONS
73	A polymorphism of the methylenetetrahydrofolate reductase gene confers susceptibility to schizophrenia and related brain changes. Schizophrenia Research, 2019, 208, 462-464.	2.0	1
74	Trait Loci Mapping and CSF Proteome. Methods in Molecular Biology, 2019, 2044, 365-376.	0.9	1
75	3P-189 High-density caveolar formation just beneath the plasma membrane during adipogenesis, as revealed by freeze-etch electron microscopy(The 46th Annual Meeting of the Biophysical Society of) Tj ETQq1 1	0. 7&4 314	rg B T /Overloo